<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161510</url>
  </required_header>
  <id_info>
    <org_study_id>2248-002</org_study_id>
    <secondary_id>2014-001494-14</secondary_id>
    <nct_id>NCT02161510</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Subjects With Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify a safe dose of MK-2248 in participants with
      Hepatitis C Virus (HCV) that mediates at least a 3 log10 reduction in viral load (VL) from
      baseline. It is anticipated that once-daily administration of a safe and well tolerated dose
      of MK-2248 will reduce VL by at least 3 log10 IU/mL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase 1b study, the pharmacokinetic (PK), pharmacodynamic (PD), and safety profile of
      MK-2248 in HCV-infected participants will be evaluated as follows: Part I will assess
      sequentially ascending MK-2248 doses from 200 mg to ≤800 mg over 4 panels (A, B, C, and D).
      Part II will assess sequentially ascending MK-2248 doses from 200 mg to ≤800 mg over 4 panels
      (E, F, G, and H). Part III will assess sequentially ascending MK-2248 doses ranging up to
      ≤800 mg in 2 panels (I and J). The potential relationship between plasma MK-2248 levels and
      VL reduction will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change from baseline in VL</measure>
    <time_frame>Up to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinue from study treatment due to an AE</measure>
    <time_frame>Up to Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at 24 hours post-dose (C24hr) of MK-2248 and circulating metabolite(s)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma-concentration curve at zero to 24 hours post-dose (AUC[0-24hr]) of MK-2248 and circulating metabolite(s)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed post-dose plasma concentration (Cmax) of MK-2248 and circulating metabolite(s)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time post-dose at which the maximum observed plasma concentraton (Tmax) of MK-2248 and circulating metabolite(s) occurs</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required for Cmax to decrease by half (apparent t1/2) of MK-2248 and circulating metabolite(s) in plasma</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of MK-2248 and circulating metabolite(s) in plasma</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance (amount of drug cleared relative to the total systemically available amount per unit time [CL/F]) of MK-2248 in plasma</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (V/F) of MK-2248 in plasma</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Part I: MK-2248 200 mg (Panel A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2248 ≤800 mg (Panel B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2248 ≤800 mg (Panel C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: MK-2248 ≤800 mg (Panel D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: MK-2248 200 mg (Panel E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: MK-2248 ≤800 mg (Panel F)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: MK-2248 ≤800 mg (Panel G)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: MK-2248 ≤800 mg (Panel H)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III: MK-2248 ≤800 mg (Panel I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III: MK-2248 ≤800 mg (Panel J)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2248</intervention_name>
    <description>MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days</description>
    <arm_group_label>Part I: MK-2248 200 mg (Panel A)</arm_group_label>
    <arm_group_label>Part I: MK-2248 ≤800 mg (Panel B)</arm_group_label>
    <arm_group_label>Part I: MK-2248 ≤800 mg (Panel C)</arm_group_label>
    <arm_group_label>Part I: MK-2248 ≤800 mg (Panel D)</arm_group_label>
    <arm_group_label>Part II: MK-2248 200 mg (Panel E)</arm_group_label>
    <arm_group_label>Part II: MK-2248 ≤800 mg (Panel F)</arm_group_label>
    <arm_group_label>Part II: MK-2248 ≤800 mg (Panel G)</arm_group_label>
    <arm_group_label>Part II: MK-2248 ≤800 mg (Panel H)</arm_group_label>
    <arm_group_label>Part III: MK-2248 ≤800 mg (Panel I)</arm_group_label>
    <arm_group_label>Part III: MK-2248 ≤800 mg (Panel J)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of chronic HCV defined by positive serology for HCV or positive HCV
             RNA for at least 6 months and detectable HCV RNA in peripheral blood ≥10^5 IU/mL at
             screening

          -  Body Mass Index (BMI) ≥18 to &lt;37 kg/m^2

          -  in good health other than HCV infection with normal laboratory values

        Exclusion Criteria:

          -  history of clinically significant and not stably controlled endocrine,
             gastrointestinal, cardiovascular, hematological, hepatic (excepting HCV infection),
             immunological, renal, respiratory, genitourinary, or major neurological abnormalities
             or disease

          -  history of cancer other than adequately treated non-melanomatous skin carcinoma,
             malignancies which have been successfully treated ≥10 years prior with no recurrence,
             or cancer that is unlikely to sustain a recurrence for the duration of the trial

          -  history of significant multiple and/or severe allergies or has had an anaphylactic
             reaction or significant intolerability to prescription or non-prescription drugs or
             food

          -  positive for hepatitis B surface antigen or human immunodeficiency virus

          -  had major surgery or lost 1 unit of blood within 4 weeks prior to screening

          -  QTc interval ≥470 msec (males) or ≥480 msec (females)

          -  received prior treatment with other HCV inhibitors

          -  clinical or laboratory evidence of decompensated liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <last_update_submitted>June 5, 2015</last_update_submitted>
  <last_update_submitted_qc>June 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

